Drug class
Oral plasma kallikrein inhibitor; hereditary angioedema prophylactic agent
Mechanism of action
Selectively inhibits plasma kallikrein, reducing cleavage of high-molecular-weight kininogen and formation of bradykinin, a mediator of hereditary angioedema attacks. The previous CYP2D6 mechanism assignment was incorrect; CYP2D6 is relevant to drug-interaction considerations, not its primary pharmacological mechanism.
General use cases
- Routine prevention of recurrent attacks of hereditary angioedema (HAE) in adults and paediatric patients aged 12 years and older; not indicated for treatment of an acute HAE attack
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
